335 related articles for article (PubMed ID: 15964061)
1. Oxidative stress effects fibrinolytic system in dialysis uraemic patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2006; 117(5):517-22. PubMed ID: 15964061
[TBL] [Abstract][Full Text] [Related]
2. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
[TBL] [Abstract][Full Text] [Related]
3. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
[TBL] [Abstract][Full Text] [Related]
4. Chronic viral hepatitis C, oxidative stress and the coagulation/fibrinolysis system in haemodialysis patients.
Pawlak K; Zolbach K; Borawski J; Mysliwiec M; Kovalchuk O; Chyczewski L; Pawlak D
Thromb Res; 2008; 123(1):166-70. PubMed ID: 18452978
[TBL] [Abstract][Full Text] [Related]
5. Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 120(6):871-6. PubMed ID: 17331567
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients.
Pawlak K; Pawlak D; Myśliwiec M
Thromb Res; 2008; 121(4):543-8. PubMed ID: 17706748
[TBL] [Abstract][Full Text] [Related]
7. Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease.
Pawlak K; Pawlak D; Mysliwiec M
Clin Biochem; 2005 Aug; 38(8):700-5. PubMed ID: 15963971
[TBL] [Abstract][Full Text] [Related]
8. Relationship of oxidative stress and fibrinolysis in diabetes mellitus.
Skrha J; Hodinár A; Kvasnicka J; Hilgertová J
Diabet Med; 1996 Sep; 13(9):800-5. PubMed ID: 8891455
[TBL] [Abstract][Full Text] [Related]
9. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment.
Pawlak K; Buraczewska-Buczko A; Mysliwiec M; Pawlak D
Am J Med Sci; 2010 Jan; 339(1):5-9. PubMed ID: 19926968
[TBL] [Abstract][Full Text] [Related]
10. Impaired renal function and duration of dialysis therapy are associated with oxidative stress and proatherogenic cytokine levels in patients with end-stage renal disease.
Pawlak K; Pawlak D; Mysliwiec M
Clin Biochem; 2007 Jan; 40(1-2):81-5. PubMed ID: 17046733
[TBL] [Abstract][Full Text] [Related]
11. Global fibrinolytic capacity in children on dialysis.
Agras PI; Baskin E; Cengiz N; Kirazli S; Saatci U; Ozbek N
Thromb Res; 2005; 115(3):185-9. PubMed ID: 15617740
[TBL] [Abstract][Full Text] [Related]
12. The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients.
Pawlak K; Mysliwiec M; Pawlak D
Thromb Res; 2008; 122(3):328-35. PubMed ID: 18048089
[TBL] [Abstract][Full Text] [Related]
13. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
14. Impairment of glutathione biosynthetic pathway in uraemia and dialysis.
Alhamdani MS
Nephrol Dial Transplant; 2005 Jan; 20(1):124-8. PubMed ID: 15632350
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
Ho CH; Yuan CC; Liu SM
Gynecol Oncol; 1999 Dec; 75(3):397-400. PubMed ID: 10600296
[TBL] [Abstract][Full Text] [Related]
16. Coagulation and fibrinolysis factors in dialysis patients with and without ischemic heart disease.
Oda H; Ohno M; Ohashi H
Adv Perit Dial; 2000; 16():152-5. PubMed ID: 11045282
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
19. Enhanced fibrinolytic activity during the course of hemodialysis.
Nakamura Y; Tomura S; Tachibana K; Chida Y; Marumo F
Clin Nephrol; 1992 Aug; 38(2):90-6. PubMed ID: 1387598
[TBL] [Abstract][Full Text] [Related]
20. Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients--role of oxidative stress.
Pawlak K; Pawlak D; Mysliwiec M
Cytokine; 2005 Jul; 31(1):18-24. PubMed ID: 15896974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]